Literature DB >> 23106970

Bubble nasal CPAP, early surfactant treatment, and rapid extubation are associated with decreased incidence of bronchopulmonary dysplasia in very-low-birth-weight newborns: efficacy and safety considerations.

Charles A Friedman1, Robert C Menchaca, Mary C Baker, Clarissa K Rivas, Raymond N Laberge, Enrique H Rios, Syed H Haider, Edgar J Romero, Elizabeth B Eason, J Kennard Fraley, Mesfin Woldesenbet.   

Abstract

BACKGROUND: Current literature has been inconsistent in demonstrating that minimizing the duration of mechanical ventilation in very-low-birth-weight (VLBW) newborns reduces lung damage.
OBJECTIVE: To determine if introduction of bubble nasal CPAP (bnCPAP), early surfactant treatment, and rapid extubation (combined bnCPAP strategy) in our community-based neonatal ICU reduced bronchopulmonary dysplasia (BPD).
METHODS: This was a 7-year retrospective,single-institution review of respiratory outcomes in 633 VLBW babies before and after introduction of the combined bnCPAP strategy. Coincident changes in newborn care were taken into account with a logistic regression model.
RESULTS: The average percentage of VLBW newborns with BPD decreased to 25.8% from 35.4% (P = .02), reaching a minimum in the last post-bnCPAP year of22.1% (P = .02). When other coincident changes in newborn care during the study years were taken into account, VLBW babies in the post-bnCPAP years had a 43% lower chance of developing BPD(P = .003, odds ratio 0.43, 95% CI 0.25– 0.75). Decreases occurred in mechanical ventilation and the percentage of infants discharged on diuretics and on supplemental oxygen. Among the subset of extremely-low-birth-weight newborns, improved respiratory outcomes in the post-bnCPAP years,as compared to outcomes in the pre-bnCPAP years, included an increase in the percentage alive and off mechanical ventilation at 1 week postnatal age (P < .001), a more rapid extubation rate(P < .03), a decrease in the median days on mechanical ventilation (P = .002), and a decrease in the percentage with BPD plus died (P = .01). Post-bnCPAP extremely-low-birth-weight babies had a statistically significant decrease in retinopathy of prematurity, an increase in low-grade intraventricular hemorrhage, and a decrease in ductal ligations.
CONCLUSIONS: A combined BnCPAP strategy may contribute to a reduction of BPD, after adjusting for concurrent treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23106970     DOI: 10.4187/respcare.01998

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

Review 1.  Chronic lung disease in the preterm infant. Lessons learned from animal models.

Authors:  Anne Hilgendorff; Irwin Reiss; Harald Ehrhardt; Oliver Eickelberg; Cristina M Alvira
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

2.  Sudden versus gradual pressure wean from Nasal CPAP in preterm infants: a randomized controlled trial.

Authors:  S Amatya; M Macomber; A Bhutada; D Rastogi; S Rastogi
Journal:  J Perinatol       Date:  2017-02-23       Impact factor: 2.521

Review 3.  On the evolution of the pulmonary alveolar lipofibroblast.

Authors:  John S Torday; Virender K Rehan
Journal:  Exp Cell Res       Date:  2015-12-17       Impact factor: 3.905

Review 4.  Non-invasive Respiratory Support of the Premature Neonate: From Physics to Bench to Practice.

Authors:  Ibrahim Sammour; Sreenivas Karnati
Journal:  Front Pediatr       Date:  2020-05-08       Impact factor: 3.418

5.  Decreasing Chronic Lung Disease Associated with Bubble CPAP Technology: Experience at Five Years.

Authors:  Tricia A Miller; Jing Li; Stella Riddell; Steven C Barkley
Journal:  Pediatr Qual Saf       Date:  2020-04-10

6.  Non-invasive high-frequency oscillatory ventilation in preterm infants after extubation: a randomized, controlled trial.

Authors:  Yan Li; Qiufen Wei; Dan Zhao; Yan Mo; Liping Yao; Lingxiao Li; Wei Tan; Xinnian Pan; Jiayan Yao; Wei Dai; Danni Zhong
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.